Related Experiment Video
Updated: Mar 19, 2026
20:23
A Lectin HPLC Method to Enrich Selectively-glycosylated Peptides from Complex Biological Samples
Published on: October 1, 2009
16.6K
A lectin-based approach to detecting carcinogenesis in breast tissue
Ga Ram Wi1, Byung-In Moon2, Hyoung Jin Kim1
1Laboratory of Virology, College of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul 156-756, Republic of Korea.
Oncology Letters
|June 18, 2016
Summary
Altered glycosylation patterns in breast cancer tissues, detected by enzyme-linked lectin assays (ELLAs), show significant potential for early cancer screening. This method offers high sensitivity and specificity for breast cancer detection.
Area of Science:
- Biochemistry
- Oncology
- Biomarker Discovery
Background:
- Breast cancer research has primarily focused on protein and nucleic acid markers.
- Glycosylation alterations during cancer progression offer potential for sensitive cancer screening.
Purpose of the Study:
- To analyze glycosylation changes in breast cancer tissue using enzyme-linked lectin assays (ELLAs).
- To evaluate the potential of ELLA for high-throughput screening of breast cancer.
Main Methods:
- Collected breast cancer tissues (CCs) and normal tissues (CNs) from patients stages 0-IIIA.
- Compared mannosylation, galactosylation, sialylation, and fucosylation levels in CCs and CNs using ELLA.
- Analyzed glycosylation differences between early (stage 0-I) and advanced (stage II-III) breast cancer.
Main Results:
- Significantly enhanced mannosylation, galactosylation, sialylation, and fucosylation were observed in CCs compared to CNs across all stages.
- Advanced stage (II-III) CCs showed higher mannosylation and galactosylation than early stage (0-I) CCs.
- The ELLA system demonstrated high sensitivity (71–100%) with 100% specificity.
Conclusions:
- Enhanced glycosylation levels detected by ELLA are associated with breast tumor development.
- ELLA system exhibits high sensitivity and specificity for breast cancer detection.
- This approach holds promise for developing reliable breast cancer diagnostic procedures.
